Natera Inc (NASDAQ:NTRA) CEO Sells $178,918.40 in Stock

Share on StockTwits

Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 7,424 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $24.10, for a total value of $178,918.40. Following the completion of the sale, the chief executive officer now owns 2,268 shares in the company, valued at $54,658.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Steven Leonard Chapman also recently made the following trade(s):

  • On Tuesday, March 10th, Steven Leonard Chapman sold 1,147 shares of Natera stock. The shares were sold at an average price of $33.36, for a total value of $38,263.92.
  • On Thursday, January 16th, Steven Leonard Chapman sold 139,340 shares of Natera stock. The shares were sold at an average price of $35.00, for a total value of $4,876,900.00.
  • On Tuesday, January 7th, Steven Leonard Chapman sold 1,849 shares of Natera stock. The shares were sold at an average price of $35.00, for a total value of $64,715.00.
  • On Friday, January 3rd, Steven Leonard Chapman sold 4,739 shares of Natera stock. The shares were sold at an average price of $32.01, for a total value of $151,695.39.

NASDAQ NTRA opened at $25.90 on Friday. The business’s 50-day moving average price is $33.35 and its 200 day moving average price is $35.26. Natera Inc has a twelve month low of $16.87 and a twelve month high of $41.80. The company has a market capitalization of $2.07 billion, a PE ratio of -14.31 and a beta of 1.13. The company has a current ratio of 2.91, a quick ratio of 2.84 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 26th. The medical research company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.16. Natera had a negative return on equity of 120.68% and a negative net margin of 41.30%. The firm had revenue of $83.20 million for the quarter, compared to the consensus estimate of $77.84 million. Equities analysts predict that Natera Inc will post -2.36 EPS for the current year.

Several equities analysts recently weighed in on the company. Craig Hallum reiterated a “buy” rating and set a $49.00 target price on shares of Natera in a research report on Thursday, December 19th. Canaccord Genuity reiterated a “buy” rating and set a $46.00 target price on shares of Natera in a research report on Thursday, March 19th. BidaskClub downgraded Natera from a “buy” rating to a “hold” rating in a research report on Wednesday, March 11th. Zacks Investment Research downgraded Natera from a “buy” rating to a “hold” rating in a research report on Thursday, January 23rd. Finally, Piper Sandler increased their target price on Natera from $45.00 to $49.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $43.00.

A number of large investors have recently made changes to their positions in NTRA. Marshall Wace LLP acquired a new stake in Natera during the first quarter worth about $264,000. Russell Investments Group Ltd. acquired a new stake in Natera during the third quarter worth about $1,163,000. Tower Research Capital LLC TRC acquired a new stake in Natera during the third quarter worth about $36,000. State Street Corp increased its stake in Natera by 4.8% during the third quarter. State Street Corp now owns 2,065,518 shares of the medical research company’s stock worth $67,749,000 after acquiring an additional 95,038 shares during the last quarter. Finally, HWG Holdings LP increased its stake in Natera by 10,712.3% during the third quarter. HWG Holdings LP now owns 28,112 shares of the medical research company’s stock worth $922,000 after acquiring an additional 27,852 shares during the last quarter. Institutional investors own 91.88% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: What are benefits of a growth and income fund?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Q1 2020 EPS Estimates for Kraft Heinz Co Lifted by Analyst
Q1 2020 EPS Estimates for Kraft Heinz Co Lifted by Analyst
Research Analysts Set Expectations for Integra Lifesciences Holdings Corp’s Q1 2020 Earnings
Research Analysts Set Expectations for Integra Lifesciences Holdings Corp’s Q1 2020 Earnings
Q1 2020 EPS Estimates for Heartland Financial USA Inc  Reduced by DA Davidson
Q1 2020 EPS Estimates for Heartland Financial USA Inc Reduced by DA Davidson
Q1 2020 Earnings Estimate for Iqvia Holdings Inc  Issued By Piper Sandler
Q1 2020 Earnings Estimate for Iqvia Holdings Inc Issued By Piper Sandler
Q1 2020 EPS Estimates for Hexcel Co.  Cut by Jefferies Financial Group
Q1 2020 EPS Estimates for Hexcel Co. Cut by Jefferies Financial Group
IntriCon Co.  Expected to Earn Q1 2020 Earnings of  Per Share
IntriCon Co. Expected to Earn Q1 2020 Earnings of Per Share


 
© 2006-2020 Zolmax.